---
title: "CAMP: Phase I trial for SYNGAP1 to launch in Q4, leveraging global sites and robust preclinical data"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298494403.md"
description: "SYNGAP1, a rare neurological disorder with no approved therapies, is the focus of an upcoming phase I trial authorized in multiple countries and set to begin in Q4. The multi-cohort study uses preclinical and natural history data, with endpoints in cognitive, motor, and seizure domains. Analyst Day will provide further trial and pipeline updates.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-09T18:50:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298494403.md)
  - [en](https://longbridge.com/en/news/298494403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298494403.md)
generator: "portal-rs"
---

# CAMP: Phase I trial for SYNGAP1 to launch in Q4, leveraging global sites and robust preclinical data

SYNGAP1, a rare neurological disorder with no approved therapies, is the focus of an upcoming phase I trial authorized in multiple countries and set to begin in Q4. The multi-cohort study uses preclinical and natural history data, with endpoints in cognitive, motor, and seizure domains. Analyst Day will provide further trial and pipeline updates.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)

## Related News & Research

- [Neuro Event Labs wins CMS NTAP coverage for Nelli seizure monitoring system, up to USD 975 per case](https://longbridge.com/en/news/298310708.md)
- [Trump shrugs off AI existential threat warnings](https://longbridge.com/en/news/298678197.md)
- [OpenAI Reportedly Considers Cooperating With Other AI Companies to Slow Pace of Frontier AI Development](https://longbridge.com/en/news/298667257.md)
- [Genlight Medical raises several hundred million yuan in C and D rounds](https://longbridge.com/en/news/298266589.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**